Gsa Capital Partners LLP Nuvation Bio Inc. Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 16, 2024	SELL	$0.96 - $1.53 $180,018 - $286,904	-187,519 Reduced 81.43%	42,776 $64,000
Q3 2023 Nov 15, 2023	SELL	$1.26 - $2.1 $58,451 - $97,419	-46,390 Reduced 16.77%	230,295 $308,000
Q2 2023 Aug 14, 2023	SELL	$1.56 - $1.84 $65,331 - $77,057	-41,879 Reduced 13.15%	276,685 $498,000
Q1 2023 May 12, 2023	BUY	$1.6 - $2.48 $113,636 - $176,137	71,023 Added 28.69%	318,564 $528,000
Q4 2022 Feb 13, 2023	BUY	$1.68 - $2.5 $82,595 - $122,910	49,164 Added 24.78%	247,541 $475,000
Q3 2022 Nov 14, 2022	BUY	$0.29 - $4.04 $47,454 - $661,085	163,635 Added 471.0%	198,377 $444,000
Q2 2022 Aug 09, 2022	BUY	$3.24 - $5.85 $112,564 - $203,240	34,742 New	34,742 $113,000

152

123M

9.7K

6.5K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $480M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.